The risk of intestinal malignancy in Crohn's disease remains uncertain since risk estimates vary worldwide.
The global Crohn's disease population is growing and there is a demand for better knowledge of prognosis of this disease.
Hence, Dr Tine Jess and colleagues conducted a meta-analysis of population-based data on intestinal cancer risk in Crohn's disease.
The MEDLINE search engine and abstracts from international conferences were searched for the relevant literature by use of explicit search criteria.
All papers fulfilling the strict inclusion criteria were scrutinized for data on population size, time of follow-up, and observed to expected cancer rates.
|5 studies reporting standardized incident ratios had an overall pooled estimate of 27|
|American Journal of Gastroenterology|
The researchers used STATA meta-analysis software to perform overall pooled risk estimates.
The research team also performed meta-regression analyses of the influence of specific variables on standardized incident ratios.
The team found 6 papers that fulfilled the inclusion criteria and reported standardized incident ratios of colorectal cancer in Crohn's, varying from 1 to 2.
The pooled standardized incident ratios for colorectal cancer was significantly increased, as was the risk for colon cancer separately.
Regarding small bowel cancer, the researchers found 5 studies reporting standardized incident ratios from 3 to 67.
The team noted that the overall pooled estimate was 27.
Dr Jess' team concludes, “The present meta-analysis of intestinal cancer risk in Crohn's disease, based on population-based studies only, revealed an overall increased risk of both colorectal cancer and small bowel cancer among patients with Crohn's disease.”
“However, some of the available data were several decades old, and future studies taking new treatment strategies into account are required.”